[HTML][HTML] Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study
I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - Vaccines, 2022 - mdpi.com
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
Effectiveness of Paxlovid-a review
S Paltra, T Conrad - medRxiv, 2023 - medrxiv.org
Paxlovid is an oral treatment for mild to moderate COVID-19 cases with a high risk for severe
course of the disease. For this review, we have performed a comprehensive literature …
course of the disease. For this review, we have performed a comprehensive literature …
[HTML][HTML] New therapeutic options in mild moderate COVID-19 outpatients
C Ucciferri, A Di Gasbarro, P Borrelli, M Di Nicola… - Microorganisms, 2022 - mdpi.com
Background: In recent years, the therapeutic options for COVID have significantly improved;
however, the therapies are expensive with restricted access to drugs, and expeditious and …
however, the therapies are expensive with restricted access to drugs, and expeditious and …